OHSU

IRB #

IRB00009621

Title

An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: PIONEER AF-PCI

Principal Investigator

Saurabh Gupta

Study Purpose

The purpose of this study is to learn more about the safety of a new blood thinner drug used to reduce the formation of blood clots. Subjects in this study are people with atrial fibrillation (an irregular heart rhythm) who have had, or will soon have, a percutaneous coronary intervention (PCI) and have, or will soon receive, at least 1 stent in at least 1 artery of their heart.

Medical Condition(s)

Atrial fibrillation
Cardiovascular

Eligibility Criteria

-Male or female age 18+
-Diagnosis of atrial fibrillation
-Have had, or will soon have, a PCI (percutaneous coronary intervention) and receive at least 1 stent in at least 1 artery of the heart

Age Range

18 - 99

Healthy Volunteers Needed

No

Duration of Participation

12 months

Minors Included

No

Contact

Aynun Naher
Study Coordinator
(503) 494-3313

Sponsor

Janssen Scientific Affairs, LLC

Recruitment End

05/29/2015

Compensation Provided

Yes

Compensation

Subjects will be paid $40 for each study visit completed


Go Back